News

Fierce Pharma2d
FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns
On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...
STAT1d
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
US FDA approves pre-filled version of GSK's shingles vaccine
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...
GlaxoSmithKline to cut 150 jobs in Cambridge
GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...
BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510
GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...
GSK falls Friday, underperforms market
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
Global Stocks in the Spotlight: Alibaba, Saab, Burberry, GSK
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
pharmaphorum1d
GSK's growth plans dented by Blenrep setback
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...